• Are the current approaches for fulfilling these requirements adequate to advance development of drugs for rare or neglected diseases and individualized therapies?

  • Where along the continuum is investment needed?

 

Innovative Safe New Drugs—Financial Sectoring

 

TOM CASKEY (Drug Forum Member)

Chief Operating Officer and Director/Chief Executive Officer

University of Texas Health Science Center at Houston

 

Q&A

9:05

Session 1: Diverse Funding Organizations—Business Cases

  • Why were new approaches or models needed, and what are their advantages?

  • Are these models effective at helping to speed development and how might their impact be measured?

  • Are these viable models for advancing products in the context of individualized therapies?

  • Are federal regulatory policies adequate for helping speed development and approval of drugs for rare diseases?

Moderator:

TIMOTHY COETZEE

Executive Director

Fast Forward, LLC

9:10

OneWorld Health: A Not-for-Profit Pharmaceutical Company

 

VICTORIA HALE

Founder and Chair of the Board of Directors

Institute for OneWorld Health

9:25

Cystic Fibrosis Foundation Therapeutics’ Pipeline Approach to CFTR Drug Discovery and Development

 

DIANA WETMORE

Vice President of Alliance Management

Cystic Fibrosis Foundation Therapeutics



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement